Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor

Tory Starzyk; Rebecca Olsen; David Baltazar; Bridget Sledge; Yebabe Mengesha

doi:10.1016/j.jdcr.2021.10.033

Mucocutaneous drug reaction after treatment with Phosphatidylinositol-3-kinase inhibitor

JAAD Case Rep. 2021 Nov 16:19:25-27. doi: 10.1016/j.jdcr.2021.10.033. eCollection 2022 Jan.

Authors

Tory Starzyk¹, Rebecca Olsen², David Baltazar³, Bridget Sledge³, Yebabe Mengesha³

Affiliations

¹ Western University of Health Sciences, Lebanon, Oregon.
² A.T. Still University School of Osteopathic Medicine in Arizona, Mesa, Arizona.
³ HonorHealth Dermatology Residency, Scottsdale, Arizona.

No abstract available

Keywords: HER2, Human Epidermal growth factor Receptor 2; PI3K inhibitor; PI3K, Phosphatidylinositol-3-Kinase; alpelisib; drug reaction; immune checkpoint inhibitor; mucocutaneous.

Publication types

Case Reports